Mycozal (Fluconazole)

Fluconazole blocks the fungal enzyme 14α‑demethylase, which is essential for producing ergosterol, a key component of the fungal cell membrane. By inhibiting ergosterol synthesis, the drug compromises membrane integrity, halting fungal growth and leading to cell death while sparing most human cells.

The dosage of Mycozal is determined by the treating physician based on the infection type, severity, patient age, weight, renal and hepatic function, and other clinical factors. Only a qualified prescriber can set the appropriate regimen for each individual case.

Safety data for fluconazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Mycozal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with other azole antifungals, fluconazole offers excellent oral bioavailability and a relatively favorable safety profile, making it suitable for many outpatient infections. However, some fungal species may be resistant, and drugs like itraconazole or voriconazole may be preferred for certain deep‑tissue infections or resistant strains.

Mycozal should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Mycozal is taken orally, usually with or without food, as directed by the prescriber. The tablet or capsule should be swallowed whole with a glass of water. Patients should follow the exact schedule and duration prescribed to ensure effective treatment.

Serious adverse events, although rare, include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, anaphylaxis, and cardiac arrhythmias due to QT prolongation. Prompt medical attention is required if any of these symptoms develop.

Mycozal is contraindicated in individuals with a known hypersensitivity to fluconazole or any other azole antifungal. Patients with severe hepatic impairment or those taking medications that cause dangerous QT prolongation should avoid it unless a specialist determines that benefits outweigh risks.